Pre-Made Trebananib Biosimilar, Fusion Protein targeting ANGPT2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AGPT2/ANG2/LMPHM10 for drug discovery and mechanism of action (MOA) research

Pre-Made Trebananib Biosimilar, Fusion Protein targeting ANGPT2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AGPT2/ANG2/LMPHM10 is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Trebananib is an anti-angiopoietin peptibody comprising a peptide with angiopoietin-binding properties that is fused to the Fc (crystallizable fragment) region of an antibody and inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor. Trebananib inhibit angiogenesis and may eventually lead to an inhibition of tumor cell proliferation.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1034-1mg	1mg	3090
GMP-Bios-INN-1034-10mg	10mg	Inquiry
GMP-Bios-INN-1034-100mg	100mg	Inquiry
GMP-Bios-INN-1034-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Trebananib Biosimilar, Fusion Protein targeting ANGPT2 fused with human IGHG1 Fc (Fragment constant): Recombinant therapeutic protein targeting AGPT2/ANG2/LMPHM10
INN Name	Trebananib
Target	ANGPT2
Format	Fusion Protein
Derivation	human
Species Reactivity	human
CH1 Isotype	Fusion - IGHG1 Fc (Fragment constant) - [peptide 14-mer - peptide 14-mer]2
VD LC	Fusion - IGHG1 Fc (Fragment constant) - [peptide 14-mer - peptide 14-mer]2
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Amgen (Thousand Oaks CA USA)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	Peptide phage display library